Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2

被引:7
|
作者
Lundstrom, L. [1 ]
Bissantz, C. [2 ]
Beck, J. [1 ]
Dellenbach, M. [1 ]
Woltering, T. J. [2 ]
Wichmann, J. [2 ]
Gatti, S. [1 ,3 ]
机构
[1] NORD Neurosci, F Hoffmann La Roche Ag, pRED, Basel, Switzerland
[2] Roche Innovat Ctr Basel, Discovery Chem, Grenzacherstr 124, CH-4070 Basel, Switzerland
[3] R&D Pierre Fabre Labs, CNS Innovat Unit, Toulouse, France
关键词
Metabotropic glutamate receptor; mGlu(2); mGlu(3); mGluR; Negative allosteric modulators; Positive allosteric modulators; LY354740; LY487379; TRANSMEMBRANE BINDING POCKETS; G-PROTEIN; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DRUG DISCOVERY; MGLU2; RECEPTOR; POTENT; ANTAGONIST; INSIGHTS;
D O I
10.1016/j.neuropharm.2016.08.040
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The metabotropic glutamate receptor 2 (mGlu(2)) plays an important role in the presynaptic control of glutamate release and several mGlu(2) positive allosteric modulators (PAMs) have been under assessment for their potential as antipsychotics. The binding mode of mGlu(2) PAMs is better characterized in functional terms while few data are available on the relationship between allosteric and orthosteric binding sites. Pharmacological studies characterizing binding and effects of two different chemical series of mGlu(2) PAMs are therefore carried out here using the radiolabeled mGlu(2) agonist (3)[H]-LY354740 and mGlu(2) PAM 3[H]-2,2,2-TEMPS. A multidimensional approach to the PAM mechanism of action shows that mGlu(2) PAMs increase the affinity of (3)[H]-LY354740 for the orthosteric site of mGlu(2) as well as the number of (3)[H]-LY354740 binding sites. (3)[H]-2,2,2-TEMPS binding is also enhanced by the presence of LY354740. New residues in the allosteric rat mGlu(2) binding pocket are identified to be crucial for the PAMs ligand binding, among these Tyr(3.40) and Asn(5.46). Also of remark, in the described experimental conditions 5731A (Ser(5.42)) residue is important only for the mGlu(2) PAM LY487379 and not for the compound PAM-1: an example of the structural differences among these mGlu(2) PAMs. This study provides a summary of the information generated in the past decade on mGlu(2) PAMs adding a detailed molecular investigation of PAM binding mode. Differences among mGlu(2) PAM compounds are discussed as well as the mGlu(2) regions interacting with mGlu(2) PAM and NAM agents and residues driving mGlu(2) PAM selectivity. This article is part of the Special Issue entitled 'Metabotropic Glutamate Receptors, 5 years on'. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:115 / 127
页数:13
相关论文
共 50 条
  • [31] Molecular modeling of the transmembrane domain of mGluR2 metabotropic glutamate receptor and the binding site of its positive allosteric modulators
    E. V. Radchenko
    D. S. Karlov
    V. A. Palyulin
    N. S. Zefirov
    Doklady Biochemistry and Biophysics, 2014, 454 : 13 - 16
  • [32] Characterization of the Clinical Effect of a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor-2
    De Boer, Peter
    Sinha, Vikash
    Hoeben, Eva
    Anghelescu, Ion-George
    Kezic, Iva
    Daly, Ella
    Ceusters, Marc
    De Smedt, Heidi
    Van Nueten, Luc
    Kent, Justine M.
    BIOLOGICAL PSYCHIATRY, 2013, 73 (09) : 319S - 319S
  • [33] Discovery of dihydropyrrolopyrazinone derivatives as metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulators (PAMs)
    Tsuda, Yusuke
    Fukaya, Takayuki
    Masuda, Takahiro
    Sugishita, Aiko
    Sumitomo, Masako
    Kitamura, Atsushi
    Nishimura, Naohiro
    Masumoto, Shuji
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [34] Allosteric Modulators of Metabotropic Glutamate Receptor 5 for Treatment of Schizophrenia
    Conn, P. J.
    Stauffer, S. R.
    Zhou, S.
    Manka, J.
    Williams, R.
    Noetzel, M. J.
    Gregory, K. J.
    Vinson, P.
    Niswender, C. M.
    Jones, C. K.
    Steckler, T.
    MacDonald, G.
    Lindsley, C. W.
    CURRENT NEUROPHARMACOLOGY, 2011, 9 : 11 - 12
  • [35] Design and synthesis of novel metabotropic glutamate receptor allosteric modulators
    Stankiewicz, Anna
    Bugno, Ryszard
    Branski, Piotr
    Bojarski, Andrzej J.
    PHARMACOLOGICAL REPORTS, 2012, 64 (02) : 473 - 474
  • [36] Design and synthesis of novel metabotropic glutamate receptor allosteric modulators
    Anna Stankiewicz
    Ryszard Bugno
    Piotr Brański
    Andrzej J. Bojarski
    Pharmacological Reports, 2012, 64 : 473 - 474
  • [37] Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators
    Sheffler, Douglas J.
    Pinkerton, Anthony B.
    Dahl, Russell
    Markou, Athina
    Cosford, Nicholas D. P.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (08): : 382 - 393
  • [38] Molecular Switches of Allosteric Modulation of the Metabotropic Glutamate 2 Receptor
    Perez-Benito, Laura
    Doornbos, Maarten L. J.
    Cordomi, Arnau
    Peeters, Luc
    lavreysen, Hilde
    Pardo, Leonardo
    Tresadern, Gary
    STRUCTURE, 2017, 25 (07) : 1153 - +
  • [39] Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias
    Arsova, Angela
    Moller, Thor C.
    Hellyer, Shane D.
    Vedel, Line
    Foster, Simon R.
    Hansen, Jakob L.
    Brauner-Osborne, Hans
    Gregory, Karen J.
    MOLECULAR PHARMACOLOGY, 2021, 99 (05) : 328 - 341
  • [40] Positive allosteric modulators of metabotropic glutamate receptor 1: Characterisation and putative binding site.
    Kemp, JA
    Kew, JNC
    Mutel, V
    Jolidon, S
    Malherbe, P
    Vieira, E
    Wichmann, J
    Knoflach, F
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135